Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
7.91
+0.35 (4.63%)
May 2, 2025, 1:12 PM EDT - Market open
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Atara Biotherapeutics stock have an average target of 17.75, with a low estimate of 11 and a high estimate of 25. The average target predicts an increase of 124.40% from the current stock price of 7.91.
Analyst Consensus: Buy
* Price targets were last updated on Mar 11, 2025.
Analyst Ratings
The average analyst rating for Atara Biotherapeutics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 5 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +114.92% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 22, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $21 → $17 | Strong Buy | Maintains | $21 → $17 | +114.92% | Jan 17, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +216.06% | Dec 20, 2024 |
Financial Forecast
Revenue This Year
35.02M
from 128.94M
Decreased by -72.84%
Revenue Next Year
32.30M
from 35.02M
Decreased by -7.77%
EPS This Year
-5.12
from -11.41
EPS Next Year
-3.60
from -5.12
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 98.7M | 63.0M | 63.0M | ||
| Avg | 35.0M | 32.3M | 24.5M | ||
| Low | n/a | 2.9M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -23.5% | 79.9% | 95.0% | ||
| Avg | -72.8% | -7.8% | -24.2% | ||
| Low | - | -91.6% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.62 | -0.37 | 1.47 | ||
| Avg | -5.12 | -3.60 | -4.58 | ||
| Low | -7.95 | -7.65 | -8.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.